Answers are grounded in this paper and cite their sources.
We investigated trends of inhaled corticosteroids (ICS) use among pregnant women in Denmark from 2001 to 2023 using aggregated data from the Danish Health Data Authority, where recorded prescription redemptions in the National Prescription Register are linked to pregnancies recorded in the Danish Medical Birth Registry. Use of combination preparations (ICS and beta2-agonists) increased substantially (from 1.3 to 21 per 1000 pregnant women), corresponding to a 16-fold increase, while use of single-agent preparations (ICS) decreased gradually (from 17 to 11 per 1000 pregnant women). Combination preparations became more prevalent than single-agent preparations in 2020 among pregnant women, reflecting changes in treatment guidelines and recommendations in 2019. ICS use was higher before than during pregnancy in 2001 (22 vs. 18 per 1000 women) but lower before than during pregnancy in 2023 (30 vs. 32 per 1000 women), with the pattern reversing in 2015. Use during pregnancy was highest among the oldest women (≥ 40 years), with some variation over time, while it fluctuated substantially among the youngest women (≤ 19 years) and increased more steadily among women aged 20-39 years. Overall, our results highlight changes in ICS use among pregnant women that are well aligned with national and international asthma guidelines.
No takes yet. Share an insight, caveat, or question.
Al‐Sagit et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: